European Heart Journal — Cardiovascular Pharmacotherapy最新文献

{"title":"Systemic fibrinolysis for acute pulmonary embolism complicating acute respiratory distress syndrome in severe COVID-19: a case series.","authors":"Roberta Della Bona, Alberto Valbusa, Giovanni La Malfa, Daniele Roberto Giacobbe, Pietro Ameri, Niccolò Patroniti, Chiara Robba, Vered Gilad, Angelo Insorsi, Matteo Bassetti, Paolo Pelosi, Italo Porto","doi":"10.1093/ehjcvp/pvaa087","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvaa087","url":null,"abstract":"A peculiar form of coagulopathy develops in patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with elevations in D-dimer levels (parallel with a rise in markers of inflammation), alterations in clotting times, and thrombocytopenia. Consequently, a high incidence of venous thrombo-embolism (VTE) as well as of pulmonary embolism (PE) has been reported, and linked to increased mortality, in both Chinese and European cohorts. Clinically, this coagulation imbalance seems different from the classical disseminated intravascular coagulation with a bleeding diathesis, and results in a very high incidence of thrombotic and thrombo-embolic events with, prominently, VTE/PE of variable severity. We hereby report a retrospective case series of four patients needing mechanical ventilation for SARS-CoV-2 infection, who were diagnosed with high-risk PE and underwent systemic fibrinolysis with full-dose alteplase, with rapid haemodynamic and respiratory success in three of them. Figures 1 and 2, as well as their legends, report the most relevant clinical characteristics. Detailed descriptions of the four cases appear in the Supplementary material online. The described patients developed sudden haemodynamic instability, and the diagnosis of PE was made with bedside echocardiography, which showed either direct (‘thrombus in transit’, two patients) or indirect (right ventricular strain) signs of PE in all patients. Three cases had been treated with anticoagulants before PE: one case even suffered PE while on sodium heparin, one while on a full, weight-adjusted dose enoxaparin, and the third one 2 days after sodium heparin full anticoagulation was","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"78-80"},"PeriodicalIF":7.1,"publicationDate":"2021-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38157736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence.","authors":"Andrea Rubboli,&nbsp;Marco Valgimigli,&nbsp;Davide Capodanno,&nbsp;Gregory Y H Lip","doi":"10.1093/ehjcvp/pvaa047","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvaa047","url":null,"abstract":"<p><p>In accordance with the 2018 joint consensus document issued by the European Heart Rhythm Association (EHRA), European Society of Cardiology (ESC) Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA), and endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), as well as with other recent ESC Guidelines, the management of antithrombotic therapy of patients with atrial fibrillation undergoing percutaneous coronary intervention requires that multiple and interconnected issues, including, duration of initial triple antithrombotic therapy, selection of P2Y12 inhibitor, choice of oral anticoagulant to be combined with antiplatelet therapy, intensity of oral anticoagulation throughout combination therapy, and choice of oral anticoagulant for indefinite therapy, are addressed. To assist the responsible physician in clinical decision making, a series of practical questions are proposed and discussed in the chronological sequence they should likely be answered.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"68-73"},"PeriodicalIF":7.1,"publicationDate":"2021-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37910450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients.","authors":"Christian Jung,&nbsp;Raphael Romano Bruno,&nbsp;Bernhard Wernly,&nbsp;Michael Joannidis,&nbsp;Sandra Oeyen,&nbsp;Tilemachos Zafeiridis,&nbsp;Brian Marsh,&nbsp;Finn H Andersen,&nbsp;Rui Moreno,&nbsp;Ana Margarida Fernandes,&nbsp;Antonio Artigas,&nbsp;Bernardo Bollen Pinto,&nbsp;Joerg Schefold,&nbsp;Georg Wolff,&nbsp;Malte Kelm,&nbsp;Dylan W De Lange,&nbsp;Bertrand Guidet,&nbsp;Hans Flaatten,&nbsp;Jesper Fjølner","doi":"10.1093/ehjcvp/pvaa083","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvaa083","url":null,"abstract":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus that causes COVID-19, uses the membrane-bound form of the aminopeptidase angiotensin-converting enzyme 2 (ACE2) to enter cells. Since ACE2 is centrally involved in the regulation of the renin–angiotensin–aldosterone system (RAAS), it has been speculated that RAAS inhibitors influence clinical courses. Mehta et al. found no association between use of RAAS inhibitors and likelihood of COVID-19 testing positivity in 18 472 patients. Reynolds et al. performed a study based on data from electronic health records (5894 COVID-19 cases), where a Bayesian analysis showed no positive association of RAAS inhibitors with either a positive test result or severe illness. Mancia et al. also found no evidence in a population-based casecontrol study (6272 case-patients) for RAAS inhibitors to affect the risk of contracting COVID-19. However, although these retrospective studies report essential data, they are of limited use to inform on elderly, comorbid and severely ill patients, who represent the most vulnerable group of patients affected by COVID-19 and are also most likely treated with RAAS inhibitors within the general population. To investigate special clinical features in COVID-19, the COVIP study (Very old intensive care patients, VIP network; NCT04321265) is ongoing. COVIP prospectively includes patients equal to or above 70 years of age with proven COVID19 who are admitted to an intensive care unit (ICU). A total of 244 ICUs in 38 countries are registered to participate in COVIP. The primary endpoint is death after 30 days. Inclusion criteria are (i) age >_70 years, (ii) ICU admission, and (iii) infection with SARS-CoV-2. Furthermore, a follow-up will be performed after 3 months to assess death and quality of life. The prospective design aims to create high-quality data about risk factors, comorbidities, pre-existing frailty, ICU-treatment including treatment limitations, and the use of experimental drugs in this critically ill patient collective of elderly patients. An interim analysis was performed on 7th of May with respect to RAAS inhibitor use. In total, 324 patients were evaluated (Table 1): 157 (48%) were on RAAS inhibitors, 62 (19%) on angiotensin-converting enzyme inhibitors (ACE-I), and 95 (29%) on angiotensin II receptor blockers (ARB) before disease onset. Overall ICU mortality was 45% and was similar between patients with and without previous ARB (45% vs. 45%; P = 0.98), but lower in patients with previous ACE-I (31% vs. 49%; P = 0.01). A propensity for being on ACE-I was calculated using logistic regression, the covariates were age, body mass index, sex, sequential organ failure assessment (SOFA) score, as well as existing comorbidities of chronic heart failure, ischaemic heart disease, renal insufficiency, chronic pulmonary disease, arterial hypertension, and diabetes mellitus (Table 1). The primary endpoint was ICU mortality. Both univariable (Model 1) and mult","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"76-77"},"PeriodicalIF":7.1,"publicationDate":"2021-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa083","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38137371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity and atrial fibrillation: making inroads through fat.","authors":"Saad Javed,&nbsp;Dhiraj Gupta,&nbsp;Gregory Y H Lip","doi":"10.1093/ehjcvp/pvaa013","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvaa013","url":null,"abstract":"<p><p>The global prevalence of obesity has reached epidemic proportions, paralleled by a rise in cases of atrial fibrillation (AF). Data from epidemiological cohorts support the role of obesity as an independent risk factor for AF. Increasing evidence indicates that obesity may contribute to the AF substrate through a number of pathways including by altering epicardial adipose tissue biology, inflammatory pathways, structural cardiac remodelling, and inducing atrial fibrosis. Due to changes in pharmacokinetics and pharmacodynamics, specific therapeutic considerations are required to guide management of patients with AF including anticoagulation and rhythm control. Also, weight loss in patients with AF has been associated with reduced progression from paroxysmal to persistent AF and indeed regression from persistent to proximal AF. However, the role of dietary intervention in AF control remains to be fully elucidated and hard prospective outcome data to support weight loss are required in AF to determine its role as part of a comprehensive risk factor management strategy for AF in obese patients.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"59-67"},"PeriodicalIF":7.1,"publicationDate":"2021-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37676568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations.","authors":"Andrea Rubboli,&nbsp;Gregory Y H Lip","doi":"10.1093/ehjcvp/pvaa003","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvaa003","url":null,"abstract":"","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"197-198"},"PeriodicalIF":7.1,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37546551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Speculation is not evidence: antihypertensive therapy and COVID-19.","authors":"Giovanni de Simone,&nbsp;Costantino Mancusi","doi":"10.1093/ehjcvp/pvaa021","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvaa021","url":null,"abstract":"In 2003, a group of Chinese investigators documented that angiotensin-converting enzyme 2 (ACE2) is a functional receptor of the SARS-CoV virus. The virus–ACE2 receptor binding is thought to be responsible for cell invasion and ultimately for the manifestation of the disease. Right after the warning of a new SARS outbreak (COVID-19) related to a new coronavirus of bat origin, called SARS-CoV2, Chen et al. documented that the SARS-CoV2 receptor-binding domain also exhibits strong interaction with ACE2, followed by evidence that, similarly to SARS-CoV, SARS-CoV2 uses the ACE2 receptor for cell entry. Similarly to the SARS-CoV virus, SARS-CoV2 is thought to down-regulate the ACE2 receptor, but does not affect ACE, thus substantially reducing the counter-regulatory effect of the ACE2 system and amplifying the effect of angiotensin II (AngII). ACE2 cleaves AngII and also angiotensin I (AngI), and generates a smaller peptide, angiotensin 1-7 (Ang1-7) regulating the availability of AngII at the AT1 receptor level. Ang1-7 binds a specific Mas receptor to counteract AngII activity with opposite effects, i.e. vasodilation, anti-inflammation, and antiproliferation. The down-regulation of ACE2, also due to SARS-CoV2 infection, therefore affects the regulation of the renin–angiotensin system (RAS), especially in the lung and kidney, but also in the heart, where ACE2 is well represented. Blunting the inhibitory regulation of ACE2 would leave AngII binding on the AT1 receptor free from an important counter-regulation, with consequent uncontrolled pro-inflammatory action and further down-regulation of ACE2 due to positive feedback with AngioII. In animal experiments, during SARS-CoV infection or recombinant SARS-CoV spike protein binding to ACE2, the devastating inflammation of the lungs could be prevented by losartan, the ancestor of AT1 receptor blockers (ARBs). A review recently published clearly indicates the possibility of using ARBs as a therapy for COVID-19. Controlling AngII production with ACE inhibitors or ARBs breaks down the positive feedback reported for AngII and ACE2 and helps in restoring the ACE2 domain. The AngioI cleavage induced by ACE2 also produces another peptide, angiotensin 1-9 (Ang1-9), able to reverse experimental hypertension and thought to potentiate bradykinin action and to activate the counter-regulatory AT2 receptor. On 11 March, The Lancet. Respiratory Medicine published a letter by Fang et al. that is having great impact both in the conventional and social media, raising and spreading alarm among physicians and hypertensive patients. The hypothesis of the authors moves from a suggested, but unproven, overexpression of ACE2 in patients with diabetes and/or arterial hypertension admitted to hospital with COVID-19, and the scarce evidence that these conditions independently increase the risk of mortality . Actually, SARS-CoV2 infection, rather than overexpressing, down-regulates ACE2 and the hypothesis that COVID-19 causes ACE2 ove","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"133-134"},"PeriodicalIF":7.1,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37791864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between serum potassium levels and short-term mortality in patients with atrial fibrillation or flutter co-treated with diuretics and rate- or rhythm-controlling drugs.","authors":"Louise Hagengaard,&nbsp;Peter Søgaard,&nbsp;Marie Espersen,&nbsp;Maurizio Sessa,&nbsp;Peter Enemark Lund,&nbsp;Maria Lukács Krogager,&nbsp;Christian Torp-Pedersen,&nbsp;Kristian Hay Kragholm,&nbsp;Christoffer Polcwiartek","doi":"10.1093/ehjcvp/pvz024","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvz024","url":null,"abstract":"<p><strong>Aims: </strong>We investigated the association between potassium levels and 90-day all-cause mortality in atrial fibrillation or flutter (AF) patients co-treated with diuretics and rate- or rhythm-controlling drugs.</p><p><strong>Methods and results: </strong>During 2000-12, first-time AF patients treated with beta-blockers, amiodarone, sotalol, verapamil, or digoxin combined with any diuretic within 90 days post-AF discharge were included. Following co-treatment, a potassium measurement within 90 days after initiating diuretic treatment was required. Mortality risk associated with potassium <3.5, 3.5-3.7, 3.8-4.0, 4.5-4.7, 4.8-5.0, and >5.0 mmol/L (reference: 4.1-4.4 mmol/L) was assessed using multivariable Cox regression. In total, 14 425 AF patients were included (median age: 78 years; women: 52%). Patients most often received beta-blocker monotherapy (29%), beta-blockers and digoxin combined (25%), digoxin monotherapy (24%), amiodarone monotherapy (3%), and verapamil monotherapy (3%). Increased 90-day mortality risk was associated with <3.5 mmol/L [hazard ratio (HR) 2.05, 95% confidence interval (CI) 1.68-2.50], 3.5-3.7 mmol/L (HR 1.28, 95% CI 1.05-1.57), 4.5-4.7 mmol/L (HR 1.20, 95% CI 1.02-1.41), 4.8-5.0 mmol/L (HR 1.37, 95% CI 1.14-1.66), and >5.0 mmol/L: (HR 1.84, 95% CI 1.53-2.21). Compared with beta-blocker monotherapy, rate- or rhythm-controlling drugs did not modify the association between potassium groups and mortality risk.</p><p><strong>Conclusion: </strong>In addition to hypo- and hyperkalaemia, low and high normal range potassium levels were associated with increased 90-day mortality risk in AF patients co-treated with diuretics and rate- or rhythm-controlling drugs. These associations were independent of rate- or rhythm-controlling drugs.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"137-144"},"PeriodicalIF":7.1,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvz024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37390284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.","authors":"Domenico Acanfora,&nbsp;Marco Matteo Ciccone,&nbsp;Pietro Scicchitano,&nbsp;Chiara Acanfora,&nbsp;Gerardo Casucci","doi":"10.1093/ehjcvp/pvaa028","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvaa028","url":null,"abstract":"On 11 March 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak as a ‘pandemic’. No valid therapy for COVID-19 is actually available. Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is empirically treated with antivirals, antimalarics, tocilizumab, etc. Production of a vaccine for COVID-19 has been attempted, although approval needs time. We describe a possible, alternative approach for treating COVID-19. Lymphocyte count has been associated with increased disease severity risk. Patients who died from COVID-19 showed a significantly lower lymphocyte count than survivors, therefore this should be closely monitored. Repletion of lymphocytes could probably have beneficial effects on recovery. A recent hypothesis suggests that the inhibition of the angiotensin 1 receptor (AT1R) may provide benefits to COVID-19 patients. This hypothesis is based on the observation that the SARS-CoV-2 virus uses angiotensin-converting enzyme 2 (ACE2) as a receptor to bind the virus to the bronchial cell membrane. The enzymes ACE and ACE2 belong to the same peptidase family but have two very different physiological functions. ACE cleaves angiotensin I to generate angiotensin II (Ang II), which binds to and activates AT1R, and thus promoting vasoconstriction. ACE2 cleaves Ang II and generates angiotensin 1-7, a powerful vasodilator acting through Mas receptors. AT1R antagonists are widely used in hypertensive patients but they increase the ACE2 cardiac expression in rats and the urinary concentration of ACE2. It has been demonstrated that the binding of virus to ACE2 leads to ACE2 down-regulation,","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"135-136"},"PeriodicalIF":7.1,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37827149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.","authors":"Heinz Drexel,&nbsp;Giuseppe M C Rosano,&nbsp;Basil S Lewis,&nbsp;Kurt Huber,&nbsp;Alexander Vonbank,&nbsp;Jörn F Dopheide,&nbsp;Arthur Mader,&nbsp;Alexander Niessner,&nbsp;Gianluigi Savarese,&nbsp;Sven Wassmann,&nbsp;Stefan Agewall","doi":"10.1093/ehjcvp/pvz029","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvz029","url":null,"abstract":"<p><p>Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"97-103"},"PeriodicalIF":7.1,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvz029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37412159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The management of stress hyperglycaemia in patients experiencing acute coronary syndrome: a topic worth revisiting.","authors":"Jack Barton,&nbsp;Juan Carlos Kaski","doi":"10.1093/ehjcvp/pvz028","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvz028","url":null,"abstract":"","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"126-127"},"PeriodicalIF":7.1,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvz028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37388455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}